Wall Street analyst estimates for Alzamend Neuro Inc (ALZN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a meth...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-08 | $-0.23 | ||
| 2026-09-10 | $-0.68 | $-0.56 | -21.4% |
| 2026-07-22 | $-0.74 | $-0.67 | -10.4% |
| 2026-03-11 | $-0.58 | $-0.53 | -9.4% |
| 2025-12-09 | $-0.30 | $-0.83 | +63.9% |
| 2025-09-10 | $-1.28 | $-3.69 | +65.3% |
| 2025-07-29 | $-2.36 | $-2.70 | +12.6% |
| 2025-03-10 | $-1.71 | $-2.61 | +34.5% |
Valuation Ratios
| Price / Book | 8.33 |
| EV / EBITDA | -0.64 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $275047 | $323403 | $3.7M | $1.1M | $1.3M | $5.2M | $7.4M | $6.5M | $1.4M | $3.6M |
| Selling, General & Admin | $1.3M | $575027 | $1.3M | $3.4M | $3.6M | $7.1M | $7.4M | $3.5M | $3.1M | $5.1M |
| Operating Expenses | $1.5M | $898430 | $5.0M | $4.4M | $5.0M | $12.3M | $14.9M | $9.9M | $4.5M | $8.8M |
| Operating Income | -$1.5M | -$898000 | -$5.0M | -$4.4M | -$5.0M | -$12.3M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| EBITDA | -$21501 | $7341 | -$5.0M | -$4.4M | -$5.0M | -$12.3M | -$14.8M | -$9.9M | -$4.4M | -$8.7M |
| Interest Expense | 0 | 0 | 0 | 0 | $158803 | $46524 | $7701 | $10101 | $18029 | -$6619 |
| Pre-tax Income | -$1.6M | -$932000 | -$4.9M | -$4.4M | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$1.6M | -$932000 | -$4.9M | -$4.4M | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
| EPS | $-73.59 | $-27.71 | $-111.56 | $-83.56 | $-93.78 | $-187.31 | $-205.97 | $-132.33 | $-11.32 | $-2.63 |
| EPS (Diluted) | $-73.59 | $-27.71 | $-111.56 | $-83.56 | $-93.78 | $-187.31 | $-205.97 | $-132.33 | $-11.32 | $-2.63 |
| Shares Outstanding (Diluted) | $21334 | $33622 | $43587 | $52780 | $53815 | $65997 | $72236 | $75174 | $450799 | $3.3M |
Price
| Price | $1.83 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · APRE · BCDA · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ALZN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks